Company: GANX
Filing Date: 2025-04-17
Form Type: PRE 14A
Source: 0001558370-25-004958
Chunk: 56

Company: Gain Therapeutics, Inc.
Filing Date: 2025-04-17
Form: PRE 14A
Chunk 56
---
 counted in determining the presence of a quorum at a meeting of the Audit Committee that considers the transaction. Although we did not have a written policy for the review and approval of transactions with related persons prior to our IPO, our Board historically reviewed and approved any transaction where a director or officer had a financial interest, including the transactions described below. Prior to approving such a transaction, the material facts as to a director’s or officer’s relationship or interest in the agreement or transaction were disclosed to our Board. Our Board took this information into account when evaluating the transaction and in determining whether such transaction was fair to us and in the best interest of all our stockholders. RELATED PERSON TRANSACTIONS We describe below transactions and series of similar transactions, since the beginning of fiscal year 2023, with respect to which we were a party, will be a party, or otherwise benefited, in which:

| ● | the amount involved exceeded or will exceed the lesser of (i) $120,000; or (ii) 1% of the average of our total assets as of December 31, 2023 and 2024, and |

| ● | any of our directors, executive officers or holders of more than 5% of any class of our capital stock at the time of such transaction, or any members of their immediate family, had or will have a direct or indirect material interest. |

Agreements with Our Directors and Officers Separation Agreement with Matthias Alder On June 27, 2024, we entered into the Separation Agreement with Mr. Alder. See the disclosure above under the section titled “Employment Arrangements.” Consulting Agreement with Eric Richman On September 20, 2022, we entered into a consulting agreement with Mr. Eric Richman, who previously served as our Chief Executive Officer and is currently a member of our Board. Pursuant to the consulting agreement, Mr. Richman agreed to provide consulting services as a special advisor to the Company and the Board at the request of the Chairman of the Board or another member of the Board of the Company. The consulting agreement terminated on September 20, 2023. We paid a total of $236,000 in connection with Mr. Richman’s consulting agreement.

#### Relationship with Minoryx
We have entered into a license agreement, dated December 20, 2017, or the Minoryx License Agreement, with Minoryx Therapeutics, S.L., a company organized under the laws of Spain, or Minoryx, pursuant